NCT05777109View on ClinicalTrials.gov

Comparing of the PK, PD, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults

PHASE1UnknownINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

April 20, 2023

Primary Completion Date

April 5, 2024

Study Completion Date

April 5, 2024

Conditions
Healthy
Interventions
DRUG

HS-20090

A human IgG2 monoclonal antibody with affinity and specificity for human RANKL

DRUG

Xgeva®

Xgeva® injection (120mg) by subcutaneous injection once on the first day subcutaneous injection of 120 mg (1.7 ml)only once

Trial Locations (1)

570208

RECRUITING

Haikou People's Hospital, Haikou

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY